Title: Numinus Shuts Down Research Lab and Focuses on Clinics; Study Shows DMT Safe and Effective with SSRI; New Preprint Questions Theory of Psychedelic Neuroplasticity
Summary:
1. Numinus Wellness, a Vancouver-based company, closes its research lab and consolidates its focus on clinics in an effort to reduce expenses and generate cash flow.
2. A study conducted by Small Pharma suggests that DMT, administered to patients with major depressive disorder who are on selective serotonin reuptake inhibitors (SSRIs), is safe and effective.
3. A new preprint challenges the intracellular theory of psychedelic-induced neuroplasticity and suggests that surface receptors may play a more significant role in the effects of psychedelics.
4. Earl Blumenauer and Robert Garcia introduce the Validating Independence for State Initiatives on Organic Natural Substances Act of 2023, which aims to prevent federal intervention in states with liberalized psilocybin laws.
